Astellas Presents Update on Recently Cleared Pompe Gene Therapy Trial

After overcoming a clinical hold, Astellas presented preliminary safety and efficacy data from the Phase I/II FORTIS trial of AT845 in late-onset Pompe disease (LOPD) at the 19th Annual WORLDSymposium 2023.